Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMESS: Cyclophosphamide vs Methylprednisolone in SPMS
NCT00241254Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Dec 2005
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cyclophosphamide in secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Delay to disability deterioration as assessed by the Expanded Disability Status Scale (EDSS) at 2 years. Started Dec 2005; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT00241254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241254.